Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mosunetuzumab With Polatuzumab Vedotin in Relapsed/Refractory Follicular Lymphoma
NCT06453044Phase 2Recruiting
- Sponsor
- City of Hope
- Start
- Sep 2024
- Primary completion
- Mar 2028
- Modality
- Bispecific Antibodies, Antibody-Drug Conjugates (ADCs), Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of mosunetuzumab, polatuzumab vedotin in follicular lymphoma (FL), sponsored by City of Hope. Started Sep 2024; status: recruiting.
02
Drugs
mosunetuzumabpolatuzumab vedotin
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on NCT06453044.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06453044.